BRPI0415489A - derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica - Google Patents

derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica

Info

Publication number
BRPI0415489A
BRPI0415489A BRPI0415489-4A BRPI0415489A BRPI0415489A BR PI0415489 A BRPI0415489 A BR PI0415489A BR PI0415489 A BRPI0415489 A BR PI0415489A BR PI0415489 A BRPI0415489 A BR PI0415489A
Authority
BR
Brazil
Prior art keywords
alkoxy
alkyl
nhso
halo
optionally substituted
Prior art date
Application number
BRPI0415489-4A
Other languages
English (en)
Inventor
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Pascale Magat
Benoit Marabout
Pierre Roger
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0415489A publication Critical patent/BRPI0415489A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE N-HETEROCICLILMETILBENZAMIDAS, SUA PREPARAçãO E SUA APLICAçãO EM TERAPêUTICA". Composto de fórmula geral (I) na qual R representa ou um átomo de hidrogênio ou um grupo vinila; n representa 0 ou 1 ou 2; X representa um grupo de fórmula CH ou um átomo de nitrogênio; R, representa ou um grupo fenila ou naftila, ou um grupo ciclohexila, ou um grupo heteroarila; R~ 2~ representa ou um átomo de hidrogênio, ou um ou vários substituintes escolhidos entre os átomos de halogênio e os grupos trifluormetila, alquila, alcóxi, tienila, fenilóxi, hidróxi, mercapto, tioalquila, ciano ou um grupo de fórmula geral -NR~ 4~R~ 5~, SO~ 2~NR~ 4~R~ 5~, SO~ 2~-alquila, -SO~ 2~-fenila, -CONR~ 4~R~ 5~, -COOR~ 7~-, -CO-alquila, -CO-fenila, NHCOR~ 8~, -NHSO~ 2~-alquila, -NHSO~ 2~-fenila e -NHSO~ 2~ NR~ 4~R~ 5~ ou um grupo divalente de fórmula -OCF~ 2~O-; R~ 4~ e R~ 5~ representam cada um deles um átomo de hidrogênio ou um grupo alquila ou R~ 4~ e R~ 5~ formam com o átomo de nitrogênio que os porta um ciclo pirrolidina, um ciclo piperidina ou um ciclo morfolina. Aplicação em terapêutica.
BRPI0415489-4A 2003-10-17 2004-10-15 derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica BRPI0415489A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312165A FR2861076B1 (fr) 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
PCT/FR2004/002643 WO2005037783A2 (fr) 2003-10-17 2004-10-15 Composes tricycliques comme inhibiteurs de transport de glycine

Publications (1)

Publication Number Publication Date
BRPI0415489A true BRPI0415489A (pt) 2006-12-26

Family

ID=34385252

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415489-4A BRPI0415489A (pt) 2003-10-17 2004-10-15 derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica

Country Status (33)

Country Link
US (3) US7288656B2 (pt)
EP (1) EP1680421B1 (pt)
JP (1) JP4853918B2 (pt)
KR (1) KR101125305B1 (pt)
CN (2) CN101684118B (pt)
AT (1) ATE386036T1 (pt)
AU (1) AU2004281217B2 (pt)
BR (1) BRPI0415489A (pt)
CA (1) CA2542647C (pt)
CR (1) CR8342A (pt)
CY (1) CY1108925T1 (pt)
DE (1) DE602004011806T2 (pt)
DK (1) DK1680421T3 (pt)
EC (1) ECSP066511A (pt)
ES (1) ES2300837T3 (pt)
FR (1) FR2861076B1 (pt)
HK (2) HK1098465A1 (pt)
HR (1) HRP20080186T3 (pt)
IL (1) IL174940A (pt)
MA (1) MA28099A1 (pt)
ME (1) ME00111B (pt)
NO (1) NO335462B1 (pt)
NZ (1) NZ547163A (pt)
OA (1) OA13317A (pt)
PL (1) PL1680421T3 (pt)
PT (1) PT1680421E (pt)
RS (2) RS20060314A (pt)
RU (1) RU2346945C2 (pt)
SG (1) SG147435A1 (pt)
TN (1) TNSN06110A1 (pt)
UA (1) UA81186C2 (pt)
WO (1) WO2005037783A2 (pt)
ZA (1) ZA200603861B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
CA2561993A1 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
FR2906251B1 (fr) * 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
US9582981B2 (en) 2014-10-08 2017-02-28 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
US11817637B2 (en) 2006-11-18 2023-11-14 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
CA2691450A1 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
WO2009121872A2 (en) 2008-04-01 2009-10-08 Abbott Gmbh & Co. Kg Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
EP2373651A1 (en) * 2008-12-04 2011-10-12 Sanofi Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
CN102405222A (zh) * 2009-01-28 2012-04-04 阿斯利康(瑞典)有限公司 2-氮杂-二环[2.2.1]庚烷化合物及其用途
FR2941953B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-benzamide, leur preparation et leur application en therapeutique
FR2941954B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(6-aza-bicyclo°3.2.1!oct-1-yl)-aryl-methyl! benzamide, leur preparation et leur application en therapeutique
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
AR075837A1 (es) * 2009-03-16 2011-04-27 Sanofi Aventis Derivados de n[(2-aza-biciclo[2,1,1]hex-1-il)-aril-metil] heterobenzamida, su preparacion, composiciones farmaceuticas y su uso en el tratamiento de enfermedades neurodegenerativas
FR2943059A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
FR2944284A1 (fr) * 2009-04-14 2010-10-15 Sanofi Aventis Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
US8153653B2 (en) * 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
TR201806764T4 (tr) * 2011-11-29 2018-06-21 Vivozon Inc Yeni benzamid türevi ve bunun kullanımı.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6906227B2 (ja) * 2017-08-18 2021-07-21 国立大学法人千葉大学 ハロゲン結合ドナー／有機塩基複合型化合物及び酸塩基複合触媒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066662A (en) * 1973-12-14 1978-01-03 Science Union Et Cie., Societe Francaise De Recherche Medicale N-substituted-2-aminomethyl-3-azabicyclo(3,3,0)octane compounds
CA1223873A (en) * 1982-04-14 1987-07-07 Francis D. King Pharmaceutically active compounds
DE3780276T2 (de) * 1986-12-16 1993-02-25 Robins Co Inc A H Angstloesende n-(1-azabicyclo(2.2.2)oct-3-yl)benzamide und -thiobenzamide.
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
AU3254499A (en) * 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Glycine transport inhibitors
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AU2004281217B2 (en) 2010-07-22
US20060264441A1 (en) 2006-11-23
MA28099A1 (fr) 2006-08-01
WO2005037783A2 (fr) 2005-04-28
ATE386036T1 (de) 2008-03-15
OA13317A (fr) 2007-04-13
ES2300837T3 (es) 2008-06-16
FR2861076A1 (fr) 2005-04-22
IL174940A0 (en) 2006-08-20
FR2861076B1 (fr) 2006-01-06
AU2004281217A1 (en) 2005-04-28
KR101125305B1 (ko) 2012-03-27
RU2006116889A (ru) 2007-11-27
ME00111B (me) 2010-10-10
CY1108925T1 (el) 2014-07-02
RU2346945C2 (ru) 2009-02-20
US7288656B2 (en) 2007-10-30
JP4853918B2 (ja) 2012-01-11
HK1142887A1 (en) 2010-12-17
US20100022548A1 (en) 2010-01-28
CN1882587A (zh) 2006-12-20
DK1680421T3 (da) 2008-06-09
US7619089B2 (en) 2009-11-17
DE602004011806D1 (de) 2008-03-27
HK1098465A1 (en) 2007-07-20
HRP20080186T3 (en) 2008-05-31
CN101684118B (zh) 2013-04-10
CA2542647C (fr) 2012-07-10
ZA200603861B (en) 2007-12-27
WO2005037783A3 (fr) 2005-07-07
EP1680421A2 (fr) 2006-07-19
ECSP066511A (es) 2006-10-10
NO335462B1 (no) 2014-12-15
UA81186C2 (en) 2007-12-10
NZ547163A (en) 2010-01-29
MEP12208A (en) 2010-06-10
EP1680421B1 (fr) 2008-02-13
US8513246B2 (en) 2013-08-20
RS20060314A (en) 2008-08-07
JP2007508361A (ja) 2007-04-05
CN1882587B (zh) 2012-06-27
PL1680421T3 (pl) 2008-07-31
RS51587B (en) 2011-08-31
SG147435A1 (en) 2008-11-28
DE602004011806T2 (de) 2009-02-05
KR20060109432A (ko) 2006-10-20
CN101684118A (zh) 2010-03-31
US20080070941A1 (en) 2008-03-20
CA2542647A1 (fr) 2005-04-28
PT1680421E (pt) 2008-05-13
TNSN06110A1 (fr) 2007-11-15
IL174940A (en) 2010-11-30
NO20062030L (no) 2006-07-07
CR8342A (es) 2006-10-04

Similar Documents

Publication Publication Date Title
BRPI0415489A (pt) derivados de n-heterociclilmetilbenzamidas, sua preparação e sua aplicação em terapêutica
IL174936A0 (en) Derivatives of n-[phenyl(alkylpiperidine-2-yl) methyl] benzamide, prearation method thereof and application of same in therapeutics
HK1098456A1 (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
NO945084L (no) Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel
NO944162D0 (no) Substituerte heterosykliske karboksylsyreamider, deres fremstilling og deres anvendelse som legemiddel
ATE464291T1 (de) Indolderivate als ppar-aktivatoren
PT1599455E (pt) Derivados do ácido 4-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexiloxi)- butanóico e compostos relacionados como moduladores de ppar para o tratamento de diabetes de tipo 2 e aterosclerose
ATE347887T1 (de) Arzneimittel enthaltend substituierte 2-aryl- aminoessigsäure-verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure- verbindungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.